GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Policy Acquisition Expense

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Policy Acquisition Expense


View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Policy Acquisition Expense
Comparable Companies
VXRT PMVP THRX ANIX IFRX BDTX ABEO CDXC INO GMDA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Website
https://www.revivapharma.com
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.
Executives
Purav Patel director 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu officer: Chief Financial Officer 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp 10 percent owner 250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena director, 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc director, 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat director, 10 percent owner, officer: President and CEO 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon officer: Chief Medical Officer 19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin director 19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019